Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.


Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 6 12 2018
medline: 6 12 2018
entrez: 6 12 2018
Statut: ppublish

Résumé

In the original publication, the text in abstract section under the 'Results' section is incorrectly published as 'higher proportion of patients reached a BeAM value < 55 mg/dL.

Identifiants

pubmed: 30515716
doi: 10.1007/s13300-018-0544-8
pii: 10.1007/s13300-018-0544-8
pmc: PMC6349285
doi:

Types de publication

Journal Article Published Erratum

Langues

eng

Pagination

327

Commentaires et corrections

Type : ErratumFor

Auteurs

Ariel Zisman (A)

Endocrine Center of Aventura, Miami, FL, USA. azisman@myendocrine.com.

Terry Dex (T)

Sanofi US, Inc, Bridgewater, NJ, USA.

Michelle Roberts (M)

Sanofi US, Inc, Bridgewater, NJ, USA.

Aramesh Saremi (A)

Sanofi US, Inc, Bridgewater, NJ, USA.

Jason Chao (J)

Xinyi, Inc, Bridgewater, NJ, USA.

Vanita R Aroda (VR)

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Classifications MeSH